Ipratropiumbromide/Salbutamol Cipla

Ipratropium bromide, the active ingredient in Ipratropiumbromide/Salbutamol Cipla, is a bronchodilator presented as a combination inhalation solution for inhalation use. It treats bronchospasm associated with COPD, asthma and acute episodes in adult patients.

GNH USA supplies Ipratropiumbromide/Salbutamol Cipla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for global distribution.

Ipratropiumbromide/Salbutamol is indicated for respiratory conditions where bronchodilation is required.

Bronchospasm associated with chronic obstructive pulmonary disease (COPD): provides rapid relief of airflow limitation. Asthma: improves bronchial tone during acute episodes. Acute bronchospasm: delivers fast‑acting bronchodilation to restore ventilation.

The combination may cause a range of adverse reactions, which are classified by frequency.

Common Side Effects: - Tremor: mild shaking of the hands or limbs. - Headache: transient pain in the head region. - Throat irritation: discomfort or soreness after inhalation. - Cough: brief episodes of coughing post‑dose. - Palpitations: sensation of rapid or irregular heartbeat. - Dry mouth: reduced salivation leading to oral dryness.

Serious or Rare Side Effects: - Paradoxical bronchospasm: worsening of breathing difficulty after use. - Tachycardia or arrhythmia: significant increase in heart rate or irregular rhythm. - Angioedema: swelling of face, lips, tongue or airway. - Severe allergic reaction: rash, hives, or anaphylaxis. - Hyperglycaemia: elevated blood glucose levels, especially in diabetic patients.

Before prescribing Ipratropiumbromide/Salbutamol, clinicians should consider several safety measures.

Cardiac assessment: evaluate for arrhythmias or tachycardia risk. Paradoxical bronchospasm: monitor for worsening breathing after initial dose. Glaucoma: use with caution in patients with narrow‑angle glaucoma. Hypersensitivity: avoid in individuals with known allergy to anticholinergics or β2‑agonists. Renal/hepatic impairment: adjust monitoring in severe dysfunction. Store at ambient temperature: keep in original container, protect from moisture and light.

Ipratropiumbromide/Salbutamol can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator effect. - MAO inhibitors: increased risk of cardiovascular events. - Tricyclic antidepressants: potential for enhanced tachycardia. - Diuretics: may exacerbate hypokalaemia. - Other anticholinergics: additive anticholinergic load.

Moderate Interactions (Monitor Closely): - Theophylline: additive bronchodilation, monitor serum levels. - Inhaled corticosteroids: may increase overall bronchodilator response. - Diabetes medications: monitor blood glucose as β2‑agonists can raise glucose. - Antihistamines: may increase dry‑mouth sensation. - ACE inhibitors: observe for cough or bronchospasm augmentation.